{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Furosemide+%28Phase+1+only%29",
    "query": {
      "intervention": "Furosemide (Phase 1 only)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 6,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-22T11:14:48.065Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02575963",
      "title": "Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "AML"
      ],
      "interventions": [
        {
          "name": "Cytarabine (Phase 1 only)",
          "type": "DRUG"
        },
        {
          "name": "Lintuzumab-Ac225",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Furosemide (Phase 1 only)",
          "type": "DRUG"
        },
        {
          "name": "Spironolactone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Actinium Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2012-10",
      "completion_date": "2020-05",
      "has_results": false,
      "last_update_posted_date": "2023-07-20",
      "last_synced_at": "2026-09-22T11:14:48.065Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Lexington, Kentucky • Louisville, Kentucky + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02575963"
    },
    {
      "nct_id": "NCT05981365",
      "title": "Voxelotor CYP and Transporter Cocktail Interaction Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Voxelotor",
          "type": "DRUG"
        },
        {
          "name": "Bupropion",
          "type": "DRUG"
        },
        {
          "name": "Repaglinide",
          "type": "DRUG"
        },
        {
          "name": "Flurbiprofen",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Furosemide",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 44,
      "start_date": "2023-04-17",
      "completion_date": "2023-10-04",
      "has_results": true,
      "last_update_posted_date": "2024-11-22",
      "last_synced_at": "2026-09-22T11:14:48.065Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05981365"
    },
    {
      "nct_id": "NCT01384253",
      "title": "Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Peritoneal Neoplasms",
        "Ovarian Neoplasms",
        "Pancreatic Neoplasms",
        "Stomach Neoplasms"
      ],
      "interventions": [
        {
          "name": "²¹²Pb-TCMC-Trastuzumab",
          "type": "OTHER"
        },
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Orano Med LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2011-07",
      "completion_date": "2016-07",
      "has_results": false,
      "last_update_posted_date": "2016-09-30",
      "last_synced_at": "2026-09-22T11:14:48.065Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • San Diego, California",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01384253"
    },
    {
      "nct_id": "NCT02028689",
      "title": "Metformin and Furosemide Drug-Drug Interaction Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Lesinurad 400 mg",
          "type": "DRUG"
        },
        {
          "name": "Metformin 850 mg",
          "type": "DRUG"
        },
        {
          "name": "Furosemide 40 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ardea Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 23,
      "start_date": "2013-10",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2014-02-14",
      "last_synced_at": "2026-09-22T11:14:48.065Z",
      "location_count": 1,
      "location_summary": "Kalamazoo, Michigan",
      "locations": [
        {
          "city": "Kalamazoo",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02028689"
    },
    {
      "nct_id": "NCT07167862",
      "title": "Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Preeclampsia",
        "Preeclampsia Postpartum",
        "Preeclampsia Severe or Mild"
      ],
      "interventions": [
        {
          "name": "Butterfly iQ3 ultrasound system for determination of postpartum volume status",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Oral furosemide",
          "type": "DRUG"
        },
        {
          "name": "Intravenous furosemide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "DRUG"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 96,
      "start_date": "2026-06-15",
      "completion_date": "2028-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-09-22T11:14:48.065Z",
      "location_count": 1,
      "location_summary": "Orange, California",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07167862"
    },
    {
      "nct_id": "NCT06491550",
      "title": "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "AZD4144- Part A",
          "type": "DRUG"
        },
        {
          "name": "Placebo- Part A",
          "type": "DRUG"
        },
        {
          "name": "AZD4144- Part B",
          "type": "DRUG"
        },
        {
          "name": "Placebo- Part B",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin and Furosemide- Part C",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin, Furosemide, and AZD4144 Part C",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 91,
      "start_date": "2024-07-15",
      "completion_date": "2025-06-11",
      "has_results": false,
      "last_update_posted_date": "2025-07-04",
      "last_synced_at": "2026-09-22T11:14:48.065Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Brooklyn, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Brooklyn",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06491550"
    }
  ]
}